Compare Bill.com Holdings Inc (BILL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Eli Lilly And Co — how do they compare? Bill.com Holdings Inc trades at $49.33 (market cap $4.91B), while Eli Lilly And Co trades at $1,215.4 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 224× Bill.com Holdings Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | LLY | |
|---|---|---|
Market Cap | $4.91B | $1.10T |
Sector | Technology | Health |
52-Week High | $56.32 | $1.24K |
52-Week Low | $31.96 | $639.43 |
Enterprise Value | $4.62B | $1.14T |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $47.99, up 2.11% today, with a bullish technical signal from moving averages and strong institutional interest. The company reported revenue growth to $1.46B in 2025 and achieved profitability with net income of $23.80M, marking a significant turnaround from prior losses. Recent news highlights operational efficiency gains from a 30% workforce reduction and strategic focus on AI-driven financial automation for SMBs.
The outlook is positive with consistent earnings beats and analyst consensus favoring a buy rating, though high P/E of 213.91 indicates premium valuation. Key risks include intense fintech competition and reliance on SMB market stability. Upside to the $50.00 high price target depends on sustained margin expansion and successful AI integration.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
